Infectious disease as aetiological factor in the pathogenesis of systemic sclerosis

Netherlands Journal of Medicine

Volumn 68, Issue 11, 2010, Pages 348-353

  Radic M ^a   MartinovicKaliterna D ^a   Radic J ^a  

^a UNIVERSITY HOSPITAL SPLIT   (Croatia)

Author keywords

Infections; Pathogenesis; Systemic sclerosis

Indexed keywords

CYTOMEGALOVIRUS; HELICOBACTER PYLORI; HUMAN; HUMAN PARVOVIRUS B19; NONHUMAN; PATHOGENESIS; REVIEW; SYSTEMIC SCLEROSIS;

COMMUNICABLE DISEASES; CONNECTIVE TISSUE; CYTOMEGALOVIRUS; DISEASE PROGRESSION; EXTRACELLULAR MATRIX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INFLAMMATION; PARVOVIRUS B19, HUMAN; RISK FACTORS; SCLERODERMA, SYSTEMIC;

EID: 78649771825     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Feghali Bostwick C, Medsger TA Jr, Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum. 2003;48:1956-63.
2. Fujinami RS, Oldstone MB. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science. 1985;230:1043-5.
3. Kreuwel HT, Sherman LA. The T-cell repertoire available for recognition of self-antigens. Curr Opin Immunol. 2001;13(6):639-43.
4. Jimenez SA, Diaz A, Khalili K. Retroviruses and the pathogenesis of systemic sclerosis. Int Rev Immunol. 1995;12:159-75.
5. Dang H, Dauphinee MJ, Talal N, et al. Serum antibody to retroviral gag proteins in systemic sclerosis. Arthritis Rheum. 1991;34:1336-7.
6. Pandey JP, LeRoy EC. Human cytomegalovirus and the vasculopathies of autoimmune diseases (especially scleroderma), allograft rejection, and coronary restenosis. Arthritis Rheum. 1998;41:10-5.
7. Neidhart M, Kuchen S, Distler O, et al. Increased serum levels of antibodies against human cytomegalovirus and prevalence of autoantibodies in systemic sclerosis. Arthritis Rheum. 1999;42:389-92.
8. Nikkari S, Mertsola J, Korvenranta H. Wegener's granulomatosis and parvovirus B19 infection. Arthritis Rheum. 1994;37:1707-8.
9. Finkel TH, Torok TJ, Ferguson PJ, et al. Chronic parvovirus B19 infection and systemic necrotising vasculitis: opportunistic infection or aetiological agent. Lancet. 1994;343:1255-8.
10. Veraldi S, Mancuso R, Rizzitelli G, et al. Henoch Schonlein syndrome associated with human parvovirus B19 infection. Eur J Dermatol. 1999;9:232-3.
11. Crowson AN, Magro CM, Dawood MR. A casual role for parvovirus B19 infection in adult dermatomyositis and other autoimmune syndromes. J Cutan Pathol. 2000;27:505-15.
12. Ferri C, Longombardo G, Azzi A, Zakrzewska K. Parvovirus B19 and systemic sclerosis. Clin Exp Rheumatol. 1999;17:267-8.
13. Ferri C, Zakrzewska K, Longombardo G, et al. Parvovirus B19 infection of bone marrow in systemic sclerosis patients. Clin Exp Rheumatol. 1999;17:718-20.
14. Altschuler EL. The historical record is consistent with the recent fnding of parvovirus B19 infection of bone marrow in systemic sclerosis patients. Clin Exp Rheumatol. 2001;19:228.
15. Ray NB, Nieva DR, Seftor EA, et al. Induction of an invasive phenotype by human parvovirus B19 in normal human synovial fbroblasts. Arthritis Rheum. 2001;44:1582-6.
16. Magro CM, Nuovo GJ, Ferri C, Crowson AN, Giuggioli D, Sebastiani M. Parvoviral infection of endothelial cells and stromal fbroblasts: a possible pathogenetic role in scleroderma. J Cutan Pathol. 2004;31:43-50.
17. Sol N, Le Junter J, Vassias I, et al. Possible interactions between the NS-1 protein and tumor necrosis factor alpha pathways in erythroid cell apoptosis induced by human parvovirus B19. J Virol. 1999;73:8762-70.
18. Ferri C, Giuggioli D, Sebastian M, et al. Parvovirus B19 infection of cultured skin fbroblasts from systemic sclerosis patients. Arthritis Rheum. 2002;46:2262-3.
19. Ray NB, Nieva DRC, Seftor EA, et al. Induction of an invasive phenotype by human parvovirus B19 in normal human synovial fbroblasts. Arthritis Rheum. 2001;44:1582-6.
20. Zakrzewska K, Corcioli F, Carlsen KM, et al. Human parvovirus B19 (B19V) infection in systemic sclerosis patients. Intervirology. 2009;52:279-82
21. Vaughan JH, Shaw PX, NguyenMD, et al. Evidence of activation of 2 herpesvirus, Epstein-Barr virus and cytomegalovirus, in systemic sclerosis and normal skins. J Rheumatol. 2000;27:821-3.
22. Pandey P, LeRoy EC. Human cytomegalovirus and the vasculopathies of autoimmune diseases (especially scleroderma), allograft rejection, and coronary restenosis. Arthritis Rheum. 1998;41:10-5.
23. Hamamdzic D, Harley RA, Hazen-Martin D, LeRoy EC. Neointimal vascular lesion associated with CMV infection. BMC Musculoskeletal Disorders. 2001; 2:3.
24. Zhou YF, Shou M, Harrell RF, Yu ZX, Unger EF, Epstein SE. Chronic non-vascular cytomegalovirus infection: effects on the neointimal response to experimental vascular injury. Cardiovasc Res. 2000;45:1019-25.
25. Presti RM, Pollock AJ, Dal Canto AK, et al. Interferon g regulates acute and latent murine cytomegalovirus infection and chronic disease of the great vessels. J Exp Med. 1998;188:577-88.
26. Vaughan JH, Shaw PX, Nguyen MD, et al. Evidence of activation of 2 herpesviruses, Epstein-Barr virus and cytomegalovirus, in systemic sclerosis and normal skin. J Rheumatol. 2000;27:821-4.
27. Neidhart M, Kuchen S, Distler O, et al. Increased serum levels of antibodies against human cytomegalovirus and prevalence of autoantibodies in systemic sclerosis. Arthritis Rheum. 1999;42:389-92.
28. Ferri C, Cazzato M, Giuggioli D, Sebastiani M, Magro CM. Systemic sclerosis following human cytomegalovirus infection. Ann Rheum Dis. 2002;61:937-8.
29. Shahgasempour S, Woodroffe SB, Sullivan-Tailyour G, Garnet HM. Alteration in the expression of endothelial cell integrin receptors alpha5beta1 and alpha2beta1 and alpha6beta1 after in vitro infection with a clinical isolate of human cytomegalovirus. Arch Virol. 1997;142:125-38.
30. Pandey P, LeRoy EC. Human cytomegalovirus and the vasculopathies of autoimmune diseases (especially scleroderma), allograft rejection, and coronary restenosis. Arthritis Rheum. 1998;41:10-5.
31. Vaughan JH, Smith EA, LeRoy EC, Arnett FC, Wright TA, Medsger TJ. An autoantibody in systemic scleroderma that reacts with glycine rich sequences. Arthritis Rheum. 1995;38(Suppl 9):255.
32. Artlett CM, Cox LA, Jimenez SA. Detection of cellular microchimerism of male or female origin in systemic sclerosis patients by polymerase chain reaction analysis of HLA-Cw antigens. Arthritis Rheum. 2000;43:1062-7.
33. Artlett CM, Smith JB, Jimenez SA. Identifcation of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Engl J Med. 1998;338:1186-91.
34. Nelson JL, Furst DE, Maloney S, et al. Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. Lancet. 1998;351:559-62.
35. Waldman WJ. title typecontributorCytomegalovirus as a perturbing factor in graft/host equilibrium: havoc at the endothelial interface/title. In CMV-Related Immunopathology. Monographs in Virology, Volume 21. Edited by Scholz M, Rabenau HF, Doerr HW. Basel: Karger; 1998, 54-66.
36. Ando T, Minami M, Ishiguro K, et al. Changes in biochemical parameters related to atherosclerosis after Helicobacter pylori eradication. Aliment Pharmacol Ther. 2006;24(Suppl 4):58-64.
37. Gasbarrini A, Massari I, Serricchio M, et al. Helicobacter pylori eradication ameliorates primary Raynaud's phenomenon. Dig Dis Sci. 1998;43:1641-5.
38. Csiki Z, Gal I, Sebesi J, Szegedi G. Raynaud syndrome and eradication of Helicobacter pylori. Orv Hetil. 2000;141:2827-9.
39. Aragona P, Magazzu G, Macchia G, et al. Presence of antibodies against Helicobacter pylori and its heat-shock protein 60 in the serum of patients with Sjogren's syndrome. J Rheumatol. 1999;26:1306-11.
40. Savarino V, Sulli A, Zentilin P, Raffaella Mele M, Cutolo M. No evidence of an association between Helicobacter pylori infection and Raynaud phenomenon. Scand J Gastroenterol. 2000;35:1251-4.
41. Sulli A, Seriolo B, Savarino V, Cutolo M. Lack of correlation between gastric Helicobacter pylori infection and primary or secondary Raynaud's phenomenon in patients with systemic sclerosis. J Rheumatol. 2000;27:1820-1.
42. Herve F, Cailleux N, Benhamou Y, et al. Helicobacter pylori prevalence in Raynaud's disease. Rev Med Interne. 2006;27:736-41.
43. Danese S, Zoli A, Cremonini F, Gasbarrini A. High prevalence of Helicobacter pylori type I virulent strains in patients with systemic sclerosis. J Rheumatol. 2000;27:1568-9.
44. Kalabay L, Fekete B, Czirjak L, et al. Helicobacter pylori infection in connective tissue disorders is associated with high levels of antibodies to mycobacterial hsp65 but not to human hsp60. Helicobacter. 2002;7:250-6.
45. Radic M, Kaliterna DM, Bonacin D, Morovic Vergles J, Radic J. Correlation between Helicobacter pylori infection and systemic sclerosis activity. Rheumatology (Oxford). 2010 (in press).
46. Ebert EC. Gastric and enteric involvement in progressive systemic sclerosis. J Clin Gastroenterol. 2008; 42:5-12.
47. Hamamdzic D, Kasman LM, LeRoy EC. The role of infectious agents in the pathogenesis of systemic sclerosis. Curr Opin Rheumatol. 2002;14:694-8.
48. Arnson Y, Amital H, Guiducci S, Matucci-Cerinic M, Valentini G, Barzilai O, et al. The role of infections in the immunopathogensis of systemic sclerosis--evidence from serological studies. Ann N Y Acad Sci. 2009;1173:627-32.
49. Tachibana I, Bodorova J, Berditchevski F, Zutter MM, Helmer ME. NAG-2 a novel transmembrane-4 superfamily (TM4SF) protein that complexes with integrins and other TM4SF proteins. J Biol Chem. 1997;272:29181-9.
50. Bordron A, Dueymes M, Levy Y, et al. The binding of some human antiendothelial cell antibodies induce endothelial cell apoptosis. J Clin Invest. 1998;101:2029-35.
51. Lobo-Yeo A, Lamb JR. Superantigens as immunogens and tolerogens. Clin Exp Rheumatol. 1993;11:17-21.